Teva, Eagle Settle Suit on Pfizer’s Bendeka Rival as Trial Looms

Two units of Teva Pharmaceuticals Industries Ltd. and Eagle Pharmaceuticals Inc. settled a patent-infringement dispute with Pfizer Inc.’s Hospira over its proposed branded generic version of Bendeka days before they were set to start a federal bench trial in Delaware.

No details of the settlement were provided in agreements approved Tuesday in the U.S. District Court for the District of Delaware. Eagle and Teva subsidiaries Teva Pharmaceuticals International GmbH and Cephalon Inc. were scheduled to face Hospira in a 2018 case’s bench trial starting April 25 in Wilmington. A trial with Hospira over another Bendeka patent that was issued ...